We are live on ! Find out more
WVE icon

Wave Life Sciences

132 hedge funds and large institutions have $572M invested in Wave Life Sciences in 2024 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 54 increasing their positions, 32 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

279% more call options, than puts

Call options by funds: $549K | Put options by funds: $145K

113% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 16

69% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 32

22% more capital invested

Capital invested by funds: $469M → $572M (+$103M)

15% more funds holding

Funds holding: 115132 (+17)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

2.05% less ownership

Funds ownership: 77.91%75.86% (-2%)

Holders
132
Holders Change
+17
Holders Change %
+14.78%
% of All Funds
1.9%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
34
Increased
54
Reduced
32
Closed
16
Calls
$549K
Puts
$145K
Net Calls
+$404K
Net Calls Change
-$951K
Name Holding Trade Value Shares
Change
Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$112M
MC
2
Maverick Capital
Texas
$47.4M -$3.8M -759,725 -9%
MCM
3
M28 Capital Management
Connecticut
$43.2M -$1.87M -373,413 -5%
BlackRock
4
BlackRock
New York
$39.3M +$5.05M +1,008,962 +19%
6CM
5
683 Capital Management
New York
$33M -$1.25M -250,000 -4%
Adage Capital Partners
6
Adage Capital Partners
Massachusetts
$32.1M -$3.94M -786,341 -13%
BG
7
Bellevue Group
Switzerland
$25.3M -$2M -400,000 -9%
AG
8
Artal Group
Luxembourg
$25M +$5.23M +1,044,000 +35%
KCM
9
Kynam Capital Management
New Jersey
$24.3M
Primecap Management
10
Primecap Management
California
$17.7M -$4.42M -882,968 -23%
Point72 Asset Management
11
Point72 Asset Management
Connecticut
$12.2M -$6.2M -1,238,763 -39%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$11.8M +$2.27M +452,978 +31%
T. Rowe Price Associates
13
T. Rowe Price Associates
Maryland
$11.5M +$1.17M +233,891 +14%
Vanguard Group
14
Vanguard Group
Pennsylvania
$11.3M +$2.61M +521,665 +40%
Millennium Management
15
Millennium Management
New York
$10.1M +$5.61M +1,121,029 +218%
State Street
16
State Street
Massachusetts
$9.34M +$1.26M +250,690 +20%
TPC
17
Takeda Pharmaceutical Company
Japan
$8.31M
Fidelity Investments
18
Fidelity Investments
Massachusetts
$7.21M -$167K -33,442 -3%
WP
19
Woodline Partners
California
$5.85M -$2.22M -443,117 -32%
Morgan Stanley
20
Morgan Stanley
New York
$5.83M +$2.83M +564,464 +148%
LCM
21
Laurion Capital Management
New York
$5.38M -$1M -200,000 -19%
Northern Trust
22
Northern Trust
Illinois
$4.67M +$655K +130,841 +21%
PIM
23
Platinum Investment Management
Australia
$3.7M -$276K -55,176 -8%
IC
24
Ikarian Capital
Texas
$3.64M +$2.95M +590,088 New
DCM
25
Driehaus Capital Management
Illinois
$3.45M -$139K -27,779 -5%

WVE Hedge Fund Activity: Q1 2024 in Review

132 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Wave Life Sciences (WVE) for Q1 2024, worth a combined $572M — up 22% from $469M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new WVE positions and 16 closed out — a net gain of 18 holders — while 54 added to existing stakes and 32 trimmed.

The largest buyer was Millennium Management, adding an estimated $5.61M. The largest seller was Citadel Advisors, cutting an estimated $9.5M.

  • 132 institutional investors held Wave Life Sciences (WVE) as of Q1 2024, up from 115 in Q4 2023.
  • Funds reported $572M of Wave Life Sciences stock for Q1 2024, up 22% quarter-over-quarter.
  • 34 funds opened new Wave Life Sciences positions in Q1 2024 and 16 closed out, a net change of +18 holders.
  • The largest Wave Life Sciences buyer in Q1 2024 was Millennium Management, an estimated $5.61M added.
  • The largest Wave Life Sciences seller in Q1 2024 was Citadel Advisors, an estimated $9.5M sold.

Based on aggregated 13F filings for Q1 2024.